Trial Profile
Phase 1b Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sapanisertib (Primary) ; Letrozole
- Indications Breast cancer; HER2 negative breast cancer
- Focus Adverse reactions
- 10 Mar 2020 Planned End Date changed from 1 Dec 2019 to 14 Jun 2019.
- 10 Mar 2020 Planned primary completion date changed from 1 Dec 2019 to 14 Jun 2019.
- 10 Mar 2020 Planned initiation date changed from 1 Dec 2016 to 20 Apr 2017.